Johnson & Johnson has agreed to take over Intra-Cellular Therapies in a deal worth up to $14.6 billion – the second biopharma M&A announcement today. The $132-per-share agreement comes a few months ...
Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.
Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.
Ethereum’s base layer demand softened in November, but ETH’s underlying price supports and strong layer-2 growth show the network still has momentum despite a drop in fees and TVL.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results